- Home
- NMT vs ADCT Comparison
NMT vs ADCT Comparison
Compare NMT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMT | ADCT |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 136.1M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NMT | ADCT |
|---|---|---|
| Price | $10.49 | $1.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 44.9K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $10.02 | $0.78 |
| 52 Week High | $13.70 | $4.98 |
Technical Indicators
Market Signals| Indicator | NMT | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 25.97 | 49.99 |
| Support Level | N/A | $0.99 |
| Resistance Level | $12.89 | $1.20 |
| Average True Range (ATR) | 0.27 | 0.08 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 31.79 | 56.45 |
Price Performance
Historical ComparisonAbout NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The company has single operating segment.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).